296 related articles for article (PubMed ID: 32889615)
21. Diagnostic Positron Emission Tomography Imaging with Zirconium-89 Desferrioxamine B Squaramide: From Bench to Bedside.
Rudd SE; Noor A; Morgan KA; Donnelly PS
Acc Chem Res; 2024 May; 57(9):1421-1433. PubMed ID: 38666539
[TBL] [Abstract][Full Text] [Related]
22. Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of
Imura R; Ida H; Sasaki I; Ishioka NS; Watanabe S
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443566
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.
Salih AK; Raheem SJ; Garcia MD; Ahiahonu WK; Price EW
Inorg Chem; 2022 Dec; 61(51):20964-20976. PubMed ID: 36516446
[TBL] [Abstract][Full Text] [Related]
24. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
25. Toward Optimized
Damerow H; Cheng X; von Kiedrowski V; Schirrmacher R; Wängler B; Fricker G; Wängler C
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297549
[TBL] [Abstract][Full Text] [Related]
26. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC
Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847
[TBL] [Abstract][Full Text] [Related]
27. Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies.
Meimetis LG; Boros E; Carlson JC; Ran C; Caravan P; Weissleder R
Bioconjug Chem; 2016 Jan; 27(1):257-63. PubMed ID: 26684717
[TBL] [Abstract][Full Text] [Related]
28.
Roy J; Jagoda EM; Basuli F; Vasalatiy O; Phelps TE; Wong K; Ton AT; Hagemann UB; Cuthbertson AS; Cole PE; Hassan R; Choyke PL; Lin FI
Cancer Biother Radiopharm; 2021 May; 36(4):316-325. PubMed ID: 34014767
[No Abstract] [Full Text] [Related]
29. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional Desferrichrome Analogues as Versatile
Adams CJ; Wilson JJ; Boros E
Mol Pharm; 2017 Aug; 14(8):2831-2842. PubMed ID: 28665620
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Chelator-to-Antibody Ratio on Development of
Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961
[No Abstract] [Full Text] [Related]
32. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab-conjugated oxine-based ligand for [
Southcott L; Wharton L; Rousseau J; Merkens H; Yang H; Bénard F; Orvig C
J Inorg Biochem; 2022 Oct; 235():111936. PubMed ID: 35878576
[TBL] [Abstract][Full Text] [Related]
34. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
35.
Heskamp S; Raavé R; Boerman O; Rijpkema M; Goncalves V; Denat F
Bioconjug Chem; 2017 Sep; 28(9):2211-2223. PubMed ID: 28767228
[TBL] [Abstract][Full Text] [Related]
36. Optimisation of the Synthesis and Cell Labelling Conditions for [
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samén E; Carlsten M; Holmin S; Tran TA
Mol Imaging Biol; 2021 Dec; 23(6):952-962. PubMed ID: 34231103
[TBL] [Abstract][Full Text] [Related]
37.
Pandya DN; Bhatt NB; Almaguel F; Rideout-Danner S; Gage HD; Solingapuram Sai KK; Wadas TJ
J Nucl Med; 2019 May; 60(5):696-701. PubMed ID: 30442753
[No Abstract] [Full Text] [Related]
38. Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®.
Liapis V; Tieu W; Rudd SE; Donnelly PS; Wittwer NL; Brown MP; Staudacher AH
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):27. PubMed ID: 33205364
[TBL] [Abstract][Full Text] [Related]
39. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
40.
Benedetto R; Massicano AVF; Crenshaw BK; Oliveira R; Reis RM; Araújo EB; Lapi SE
Cancer Biother Radiopharm; 2019 Jun; 34(5):288-296. PubMed ID: 30865493
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
